Jonathan Wade Goldman

31PUBLICATIONS
295CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Electrical energy generation (incl. renewables, excl. photovoltaics)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Jul 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|Jun 01, 2026
Selpercatinib in Early-Stage <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer.

|Mar 25, 2026
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

Wungki Park, Anup Kasi, Alexander I Spira

|Mar 06, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.

Helena A Yu, Kwan Ho Tang, Aleksandra A Markovets

|Oct 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.

Melissa L Johnson, Egbert F Smit, Enriqueta Felip

|Sep 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.

Xiuning Le, Jacqulyne P Robichaux, Monique Nilsson

Pageof 6

Frequent Collaborators

6 joint publications

Melissa L Johnson

5 joint publications

Xiuning Le

4 joint publications

Myung-Ju Ahn

4 joint publications

Helena Yu